臨床神経学 – Medxy AI

CIFFREO Trial Results: Fordadistrogene Movaparvovec Fails Primary Efficacy Endpoint in Duchenne Muscular Dystrophy

By MedXY 02/24/2026

The Phase 3 CIFFREO trial for the gene therapy fordadistrogene movaparvovec failed to meet its primary efficacy endpoint in boys with Duchenne muscular dystrophy, showing no significant functional improvement over placebo and leading to the discontinuation of its clinical development.

Internal Medicine Neurology news

Preventing Epilepsy After Stroke: Insights from the Eslicarbazepine Acetate Phase 2a Trial

By MedXY 02/24/2026

The BIA-2093-213 trial evaluated eslicarbazepine acetate for preventing post-stroke epilepsy. While the primary endpoint was not met due to being underpowered, the study establishes a feasible framework for future antiepileptogenesis research using clinical risk stratification.

Neurology news

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

By MedXY 02/06/2026

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiveness in detecting amyloid-β pathology.

Infectious Diseases Neurology news

Adjunct Dexamethasone in Herpes Simplex Encephalitis: Safe but Fails to Improve Long-Term Verbal Memory in the DexEnceph Trial

By MedXY 01/29/2026

The Phase 3 DexEnceph trial found that adjunct dexamethasone is safe in adults with HSV encephalitis but does not significantly improve verbal memory scores at 26 weeks compared to aciclovir monotherapy, suggesting a need for earlier or more targeted immunomodulation.